| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5698497 | Clinical Oncology | 2016 | 8 Pages |
Abstract
SABR is well tolerated with a good radiological response and toxicity profile. Discussion within a multidisciplinary team is crucial to identify the oligometastatic patients who would probably benefit from ablative local therapy.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
F. De Rose, L. Cozzi, P. Navarria, A.M. Ascolese, E. Clerici, M. Infante, M. Alloisio, A. Testori, L. Toschi, G. Finocchiaro, A. Santoro, M. Scorsetti,